These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9166391)

  • 21. New perspectives in the treatment of postmenopausal osteoporosis: ipriflavone.
    Moscarini M; Patacchiola F; Spacca G; Palermo P; Caserta D; Valenti M
    Gynecol Endocrinol; 1994 Sep; 8(3):203-7. PubMed ID: 7847106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists.
    Gambacciani M; Cappagli B; Piaggesi L; Ciaponi M; Genazzani AR
    Calcif Tissue Int; 1997; 61 Suppl 1():S15-8. PubMed ID: 9263611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
    Välimäki MJ; Laitinen K; Patronen A; Puolijoki H; Seppänen J; Pylkkänen L; Aranko SM; Sairanen S; Blåfield H; Rekiaro M; Väisänen K; Kormano M; Mäkinen L; Salmi J; Ala-Kaila K; Perttilä J; Vesterinen K; Koivunoro K;
    Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis.
    Agnusdei D; Zacchei F; Bigazzi S; Cepollaro C; Nardi P; Montagnani M; Gennari C
    Drugs Exp Clin Res; 1989; 15(2):97-104. PubMed ID: 2661184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of ipriflavone and 1 alpha vitamin D therapy for the cessation of vertebral bone loss.
    Ushiroyama T; Okamura S; Ikeda A; Ueki M
    Int J Gynaecol Obstet; 1995 Mar; 48(3):283-8. PubMed ID: 7781871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
    McClung MR; Bolognese MA; Sedarati F; Recker RR; Miller PD
    Bone; 2009 Mar; 44(3):418-22. PubMed ID: 18950736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study.
    Ravn P; Clemmesen B; Riis BJ; Christiansen C
    Bone; 1996 Nov; 19(5):527-33. PubMed ID: 8922653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A calcium-collagen chelate dietary supplement attenuates bone loss in postmenopausal women with osteopenia: a randomized controlled trial.
    Elam ML; Johnson SA; Hooshmand S; Feresin RG; Payton ME; Gu J; Arjmandi BH
    J Med Food; 2015 Mar; 18(3):324-31. PubMed ID: 25314004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soymilk or progesterone for prevention of bone loss--a 2 year randomized, placebo-controlled trial.
    Lydeking-Olsen E; Beck-Jensen JE; Setchell KD; Holm-Jensen T
    Eur J Nutr; 2004 Aug; 43(4):246-57. PubMed ID: 15309425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study.
    Gonnelli S; Cepollaro C; Montomoli M; Gennari L; Montagnani A; Palmieri R; Gennari C
    Clin Endocrinol (Oxf); 1997 Jan; 46(1):55-61. PubMed ID: 9059558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
    Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
    Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture.
    Simon JA; Recknor C; Moffett AH; Adachi JD; Franek E; Lewiecki EM; McClung MR; Mautalen CA; Ragi-Eis S; Nicholson GC; Muschitz C; Nuti R; Törring O; Wang A; Libanati C
    Menopause; 2013 Feb; 20(2):130-7. PubMed ID: 23010883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen.
    Nozaki M; Hashimoto K; Inoue Y; Ogata R; Okuma A; Nakano H
    Int J Gynaecol Obstet; 1998 Jul; 62(1):69-75. PubMed ID: 9722129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.
    Devogelaer JP; Broll H; Correa-Rotter R; Cumming DC; De Deuxchaisnes CN; Geusens P; Hosking D; Jaeger P; Kaufman JM; Leite M; Leon J; Liberman U; Menkes CJ; Meunier PJ; Reid I; Rodriguez J; Romanowicz A; Seeman E; Vermeulen A; Hirsch LJ; Lombardi A; Plezia K; Santora AC; Yates AJ; Yuan W
    Bone; 1996 Feb; 18(2):141-50. PubMed ID: 8833208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
    Thiébaud D; Burckhardt P; Kriegbaum H; Huss H; Mulder H; Juttmann JR; Schöter KH
    Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
    Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
    Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of cyclic therapy with intranasal carbocalcitonin in healthy spontaneous postmenopausal women.
    De Aloysio D; Pansini F; Campobasso C; Zanotti L; Abbruzzese AD; Mauloni M; Bottiglioni F
    Clin Exp Obstet Gynecol; 1996; 23(2):87-93. PubMed ID: 8737620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.